Biblio Discovery — Demo Discovery Service

5 results for "Root, Adam R."

Showing 1–5 · 0.23 seconds · RSS

  1. Journal Article Full text

    Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3

    Rampuria, Pragya; Mosyak, Lidia; Root, Adam R. et al.

    Sci Rep · 2023 · English · PubMed Central

    The intestinal epithelial receptor Guanylyl Cyclase C (GUCY2C) is a tumor-associated cell surface antigen expressed across gastrointestinal malignancies that can serve as an efficacious target for colorectal cancer immunotherapy. Here, we describe a yeast surface-display approach combined with an…

  2. Journal Article Full text

    A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice

    Fisher, Timothy S.; Hooper, Andrea T.; Lucas, Justin et al.

    Cancer Immunol Immunother · 2017 · English · PubMed Central

    Strong evidence exists supporting the important role T cells play in the immune response against tumors. Still, the ability to initiate tumor-specific immune responses remains a challenge. Recent clinical trials suggest that bispecific antibody-mediated retargeted T cells are a promising…

  3. Journal Article Full text

    Illuminating protein space with a programmable generative model

    Ingraham, John B.; Baranov, Max; Costello, Zak et al.

    Nature · 2023 · English · PubMed Central

    …proteins exhibit atomistic agreement with Chroma samples (a backbone root-mean-square deviation of around 1.0 Å). With this unified approach to protein design, we hope to accelerate the programming of protein matter to benefit human health, materials science and synthetic biology.

  4. Journal Article Full text

    Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

    Root, Adam R.; Cao, Wei; Li, Bilian et al.

    Antibodies (Basel) · 2016 · English · PubMed Central

    Bispecific antibodies offer a promising approach for the treatment of cancer but can be challenging to engineer and manufacture. Here we report the development of PF-06671008, an extended-half-life dual-affinity re-targeting (DART(®)) bispecific molecule against P-cadherin and CD3 that demonstrates…

  5. Journal Article Full text

    Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors

    Root, Adam R.; Guntas, Gurkan; Katragadda, Madan et al.

    MAbs · 2021 · English · PubMed Central

    We report here the discovery and optimization of a novel T cell retargeting anti-GUCY2C x anti-CD3ε bispecific antibody for the treatment of solid tumors. Using a combination of hybridoma, phage display and rational design protein engineering, we have developed a fully humanized and manufacturable…